CTLA4 and rheumatoid arthritis: Interestingly, at study entry, IL-10 serum levels were higher in RA patients with early disease (IL-10: p = 0.042), reaching serum levels comparable to baseline after 6 and 12 months of CTLA4-Ig treatment (Fig. 2A).